Overview

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To investigate the tolerability and safety of ASTX727 in Japanese subjects with lower-risk MDS.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.